Allergen-specific immunotherapy increases plasma gelsolin levels.

Area of Science:

• Immunology
• Biochemistry

Background:

• Allergic asthma and rhinitis patients exhibit elevated peripheral blood cell apoptosis.
• Apoptosis markers may predict immunotherapy response in allergic rhinitis.

Purpose of the Study:

• To investigate if apoptosis markers predict immunotherapy response in allergic rhinitis.
• To examine plasma levels of gelsolin, sFas, Fas-L, CCL17, and TIMP-1 in allergic rhinitis patients undergoing immunotherapy.

Main Methods:

• 58 young adults with allergic rhinitis were recruited.
• Plasma samples were analyzed pre- and post-immunotherapy using ELISA.
• Levels of gelsolin, sFas, Fas-L, CCL17, and TIMP-1 were measured.

Main Results:

• Plasma gelsolin levels were significantly higher in patients receiving immunotherapy compared to those not on immunotherapy.
• Gelsolin levels in immunotherapy patients were similar to healthy controls.
• No significant differences in sFas, Fas-L, CCL17, or TIMP-1 levels were observed between groups.

Conclusions:

• Allergen-specific immunotherapy leads to increased plasma gelsolin levels.
• Gelsolin, an antioxidant and antiapoptotic protein, may be a biomarker for immunotherapy efficacy.